About Nuvectra (NASDAQ:NVTR)
Nuvectra Corporation, a neuromodulation medical device company, develops and commercializes its neurostimulation technology platform for the treatment of various disorders in neuroscience and clinical markets in Europe. The company offers Algovita spinal cord stimulation system that is used for the treatment of chronic pain of the trunk and limbs. It also provides neural interface systems, including microelectrode arrays, probes, and electrode instrumentation and accessories; and develops Virtis, a sacral nerve stimulation system for the treatment of chronic urinary retention and the symptoms of overactive bladder. The company was founded in 2008 and is headquartered in Plano, Texas.
Industry, Sector and Symbol
Industry Surgical & medical instruments
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NVTR
CUSIPN/A
Phone214-474-3103
Debt
Debt-to-Equity Ratio0.54%
Current Ratio2.81%
Quick Ratio2.50%
Price-To-Earnings
Trailing P/E Ratio-3.31
Forward P/E Ratio-3.83
P/E GrowthN/A
Sales & Book Value
Annual Sales$31.84 million
Price / Sales6.17
Cash FlowN/A
Price / CashN/A
Book Value$4.47 per share
Price / Book3.11
Profitability
EPS (Most Recent Fiscal Year)($4.22)
Net Income$-44,600,000.00
Net Margins-140.09%
Return on Equity-72.64%
Return on Assets-46.96%
Miscellaneous
Employees195
Outstanding Shares14,150,000
Nuvectra (NASDAQ:NVTR) Frequently Asked Questions
What is Nuvectra's stock symbol?
Nuvectra trades on the NASDAQ under the ticker symbol "NVTR."
How were Nuvectra's earnings last quarter?
Nuvectra (NASDAQ:NVTR) posted its quarterly earnings data on Tuesday, March, 6th. The company reported ($0.80) EPS for the quarter, topping the consensus estimate of ($1.15) by $0.35. The firm earned $11.96 million during the quarter. Nuvectra had a negative return on equity of 72.64% and a negative net margin of 140.09%. View Nuvectra's Earnings History.
When is Nuvectra's next earnings date?
What price target have analysts set for NVTR?
4 brokers have issued 1-year price objectives for Nuvectra's shares. Their forecasts range from $12.00 to $12.00. On average, they anticipate Nuvectra's stock price to reach $12.00 in the next year. View Analyst Ratings for Nuvectra.
Who are some of Nuvectra's key competitors?
Some companies that are related to Nuvectra include Utah Medical Products (UTMD), Antares Pharma (ATRS), Endologix (ELGX), Tandem Diabetes Care (TNDM), Pulse Biosciences (PLSE), GenMark Diagnostics (GNMK), Orthopediatrics (KIDS), T2 Biosystems (TTOO), Cytosorbents (CTSO), SeaSpine (SPNE), Iradimed (IRMD), Restoration Robotics (HAIR), Apollo Endosurgery (APEN), Invuity (IVTY), Alphatec (ATEC), Obalon Therapeutics (OBLN), Arch Therapeutics (ARTH) and Presbia (LENS).
Who are Nuvectra's key executives?
Nuvectra's management team includes the folowing people:
- Mr. Scott F. Drees, CEO & Director (Age 60)
- Mr. Joseph Paul Hanchin, Pres (Age 56)
- Mr. Walter Z. Berger, COO, CFO & Exec. VP (Age 62)
- Dr. Norbert Kaula Ph.D., Chief Technology Officer
- Ms. Melissa G. Beare, Exec. VP, Gen. Counsel & Corp. Sec. (Age 43)
Has Nuvectra been receiving favorable news coverage?
Headlines about NVTR stock have trended somewhat positive recently, according to Accern Sentiment. The research firm identifies positive and negative news coverage by reviewing more than twenty million blog and news sources. Accern ranks coverage of companies on a scale of -1 to 1, with scores closest to one being the most favorable. Nuvectra earned a news impact score of 0.07 on Accern's scale. They also assigned media headlines about the company an impact score of 45.82 out of 100, meaning that recent news coverage is somewhat unlikely to have an effect on the company's share price in the near term.
How do I buy shares of Nuvectra?
Shares of NVTR can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nuvectra's stock price today?
One share of NVTR stock can currently be purchased for approximately $13.89.
How big of a company is Nuvectra?
Nuvectra has a market capitalization of $193.24 million and generates $31.84 million in revenue each year. The company earns $-44,600,000.00 in net income (profit) each year or ($4.22) on an earnings per share basis. Nuvectra employs 195 workers across the globe.
How can I contact Nuvectra?
Nuvectra's mailing address is 5830 GRANITE PKWY SUITE 1100, PLANO TX, 75024. The company can be reached via phone at 214-474-3103 or via email at [email protected]
MarketBeat Community Rating for Nuvectra (NVTR)
MarketBeat's community ratings are surveys of what our community members think about Nuvectra and other stocks. Vote "Outperform" if you believe NVTR will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NVTR will underperform the S&P 500 over the long term. You may vote once every thirty days.
Nuvectra (NASDAQ:NVTR) Price Target and Consensus Rating
(How are Consensus Ratings Calculated?) MarketBeat calculates consensus analyst ratings for stocks using the most recent rating from each Wall Street analyst that has rated a stock within the last twelve months. Each analyst's rating is normalized to a standardized rating score of 1 (sell), 2 (hold), 3 (buy) or 4 (strong buy). Analyst consensus ratings scores are calculated using the mean average of the number of normalized sell, hold, buy and strong buy ratings from Wall Street analysts. Each stock's consensus analyst rating is derived from its calculated consensus ratings score (0-1.5 = Sell, 1.5-2.5 = Hold, 2.5-3.5 = Buy, >3.5 = Strong Buy). MarketBeat's consensus price targets are a mean average of the most recent available price targets set by each analyst that has set a price target for the stock in the last twelve months. MarketBeat's consensus ratings and consensus price targets may differ from those calculated by other firms due to differences in methodology and available data.
4 Wall Street analysts have issued ratings and price targets for Nuvectra in the last 12 months. Their average twelve-month price target is $12.00, suggesting that the stock has a possible downside of 13.61%. The high price target for NVTR is $12.00 and the low price target for NVTR is $12.00. There are currently 4 buy ratings for the stock, resulting in a consensus rating of "Buy."
| Today | 30 Days Ago | 90 Days Ago | 180 Days Ago |
| Consensus Rating: | Buy | Buy | Buy | Buy |
| Consensus Rating Score: | 3.00 | 3.00 | 2.50 | 2.50 |
| Ratings Breakdown: | 0 Sell Rating(s)
0 Hold Rating(s)
4 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
0 Hold Rating(s)
3 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) | 0 Sell Rating(s)
1 Hold Rating(s)
1 Buy Rating(s)
0 Strong Buy Rating(s) |
| Consensus Price Target: | $12.00 | $12.00 | $12.00 | $13.00 |
| Price Target Upside: | 13.61% downside | 2.65% upside | 16.62% upside | 1.09% upside |
Nuvectra (NASDAQ:NVTR) Consensus Price Target History
Nuvectra (NASDAQ:NVTR) Analyst Ratings History
Show:
(Data available from 4/19/2016 forward)
Nuvectra (NASDAQ:NVTR) Dividend History by Quarter
| Announced | Period | Amount | Yield | Ex-Dividend Date | Record Date | Payable Date |
|---|
(Data available from 1/1/2013 forward)
Nuvectra (NASDAQ NVTR) Insider Trading and Institutional Ownership History
Insider Ownership Percentage: 4.60%
Institutional Ownership Percentage: 46.83%
Nuvectra (NASDAQ NVTR) Insider Trading History
| Transaction Date | Insider Name | Title | Buy/Sell | Number of Shares | Average Share Price | Total Transaction | Shares Held After Transaction | Details |
|---|
| 8/11/2017 | Scott F Drees | CEO | Buy | 10,000 | $11.72 | $117,200.00 | 125,180 |  |
| 5/30/2017 | Scott F Drees | CEO | Buy | 7,395 | $10.41 | $76,981.95 | 99,136 | |
| 5/25/2017 | Scott F Drees | CEO | Buy | 2,605 | $9.92 | $25,841.60 | 90,041 | |
| 3/16/2017 | Joseph A Miller | Director | Buy | 25,000 | $6.11 | $152,750.00 | 35,743 | |
| 3/14/2017 | Scott F Drees | CEO | Buy | 25,000 | $6.21 | $155,250.00 | 7,900 | |
| 1/4/2017 | Thomas Kelley Hickman | EVP | Sell | 133 | $5.36 | $712.88 | 582 | |
| 5/19/2016 | David D Johnson | Director | Buy | 30,000 | $14.02 | $420,600.00 | 3,550 | |
(Data available from 1/1/2013 forward)
Nuvectra (NASDAQ NVTR) News Headlines
| Source: |
|
Nuvectra (NASDAQ:NVTR) SEC Filings
This page is loading this company's SEC Filings. Please wait...
Financials are not available for this stock.
Nuvectra (NASDAQ NVTR) Stock Chart for Thursday, April, 19, 2018
Loading chart…
